25 Mar 2025
13m
Oxford, UK based Greywolf Therapeutics is pursuing cancer and autoimmune indications by attempting to target T-cells at their first signal of activation - an approach the company leads the field on
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.